Influenza Vaccines Generated by Reverse Genetics

  • K. Subbarao
  • J. M. Katz
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 283)


Influenza viruses cause annual epidemics and occasional pandemics of acute respiratory disease. Vaccination is the primary means to prevent and control the disease. However, influenza viruses undergo continual antigenic variation, which requires the annual reformulation of trivalent influenza vaccines, making influenza unique among pathogens for which vaccines have been developed. The segmented nature of the influenza virus genome allows for the traditional reassortment between two viruses in a coinfected cell. This technique has long been used to generate strains for the preparation of either inactivated or live attenuated influenza vaccines. Recent advancements in reverse genetics techniques now make it possible to generate influenza viruses entirely from cloned plasmid DNA by cotransfection of appropriate cells with 8 or 12 plasmids encoding the influenza virion sense RNA and/or mRNA. Once regulatory issues have been addressed, this technology will enable the routine and rapid generation of strains for either inactivated or live attenuated influenza vaccine. In addition, the technology offers the potential for new vaccine strategies based on the generation of genetically engineered donors attenuated through directed mutation of one or more internal genes. Reverse genetics techniques are also proving to be important for the development of pandemic influenza vaccines, because the technology provides a means to modify genes to remove virulence determinants found in highly pathogenic avian strains. The future of influenza prevention and control lies in the application of this powerful technology for the generation of safe and more effective influenza vaccines.


Influenza Virus Influenza Vaccine Reverse Genetic Live Attenuate Influenza Vaccine Inactivate Influenza Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Belshe RB, Gruber WC, Mendelman PM, et al. (2000) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant ( A/Sydney) not contained in the vaccine. J Pediatr 136: 168–175PubMedCrossRefGoogle Scholar
  2. Belshe RB, Mendelman PM, Treanor J, et al. (1998) The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Eng J Med 338: 1405–1412CrossRefGoogle Scholar
  3. Beyer WEP, Palache AM, de Jong JC, Osterhaus ADME (2002) Cold-adapted influenza vaccine versus inactivated vaccine: systematic vaccine reactions, local and systemic antibody response, and vaccine efficacy A meta-analysis. Vaccine 20: 1340–1353PubMedCrossRefGoogle Scholar
  4. Bridges CB, Thompson WW Meltzer et al. (2000) Effectiveness and cost benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284: 1655–1663PubMedCrossRefGoogle Scholar
  5. Centers for Disease Control and Prevention (2002) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mort. Wkly Rep 51/No.RR-3: 1–31Google Scholar
  6. Cha T-A, Kao K, Zhao J, et al. (2002) Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Micro 38: 839–845Google Scholar
  7. Chen W, Calco PA, Malide D, et al. (2001) A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 7: 1306–12PubMedCrossRefGoogle Scholar
  8. Clements ML, Murphy BR (1986) Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Micro 23: 66–72Google Scholar
  9. Clements ML, Subbarao EK, Fries LF, Karron RA, London WT, Murphy BR (1992) Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Micro 30: 655–662Google Scholar
  10. Cox NJ, Bender CA (1995) The molecular epidemiology of influenza virus. Sem Virol 6: 359–370CrossRefGoogle Scholar
  11. Cox NJ, Brammer TL, Regnery HL (1994) Influenza: Global surveillance for epidemic and pandemic variants. Eur J Epidemiol 10: 467–470Google Scholar
  12. Cox NJ, Kitame F, Kendal AP, Maassab HF, Naeve C (1988) Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann/ Arbor/6/60 (H2N2). Virology 167: 553–567Google Scholar
  13. Edwards KM, Dupont WD, Westrich MK, Plummer Jr., WD, Palmer PS, Wright PF (1994) A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169: 68–76PubMedCrossRefGoogle Scholar
  14. Enami M, Palese P (1991) High-efficiency formation of influenza virus transfectants. Journal of Virology. 65: 2711–3PubMedGoogle Scholar
  15. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG and Garcia-Sastre A (1999) Rescue of influenza A virus from recombinant DNA. Journal of Virology 73: 9679–82PubMedGoogle Scholar
  16. Garcia-Sastre A, Egorov A, Matassov D, et al. (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252: 324–330PubMedCrossRefGoogle Scholar
  17. Govaert TME, Thifs CTMCN Masurel N, Sprenger MJW Dinant GJ, Knottnerus JA (1994). Efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 272: 1661–1665PubMedCrossRefGoogle Scholar
  18. Gregory V, Bennett M, Orkhan MH, Al Hajjar S, Varsano N, Mendelson E, Zambon M, Ellis J, Hay A, Lin YP (2002) Emergence of influenza A H1N2 reassortant viruses in the human population during 2001. Virology. 300: 1–7PubMedCrossRefGoogle Scholar
  19. Gruber WC, Kirschner K, Tollefson S, et al. (1993) Comparison of monovalent and trivalent live attenuated influenza vaccines in young children. J Infect Dis 168: 5360Google Scholar
  20. Guo YJ, Li JW, Cheng I, et al. (1999) Discovery of humans infected by avian influenza A (H9N2) virus. Chinese J Exp Clin Virol 15: 105–108Google Scholar
  21. Herlocher ML, Clavo A, Maassab HF (1996) Sequence comparison of A/AA/6/60 influenza viruses: mutations which may contribute to attenuation. Virus Res 42: 1125CrossRefGoogle Scholar
  22. Hoffmann E, Krauss S, Perez D, Webby R and Webster RG (2002a) Eight-plasmid system of rapid generation of influenza virus vaccines. Vaccine 20: 3165–3170PubMedCrossRefGoogle Scholar
  23. Hoffmann E, Mahmood K, Yang C-F, Webster RG, Greenberg HB and Kemble G (2002b) Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci USA 99: 11411–11416PubMedCrossRefGoogle Scholar
  24. Hoffmann E, Neumann G, Hobom G, Webster RG and Kawaoka Y (2000a) “Ambisense” approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 267:310–317Google Scholar
  25. Hoffmann E, Neumann G, Kawaoka Y, Hobom G and Webster RG (2000b) A DNA transfection system for generation of influenza A virus from eight plasmids. Proceedings of the National Academy of Sciences of the United States of America 97: 6108–6113PubMedCrossRefGoogle Scholar
  26. Hoffmann E, Stech J, Guan Y, Webster RG and Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Archives of Virology 146: 2275–2289PubMedCrossRefGoogle Scholar
  27. Izurieta HS, Thompson WW, Kramarz P, et al. (2000) Influenza and the rates of hos- pitalization for respiratory disease among infants and young children. New Eng J Med 342: 232–9PubMedCrossRefGoogle Scholar
  28. Jin H, Lu B, Zhou H et al. (2003) Multiple amino acid residues confer temperature-sensitivity to human influenza virus vaccine strain (FluMistTM) derived from ca A/Ann Arbor/6/60. Virology 306: 18–24PubMedCrossRefGoogle Scholar
  29. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF (1986) Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 154: 121–127PubMedCrossRefGoogle Scholar
  30. Karron RA, Steinhoff MC, Subbarao EK, et al. (1995) safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 14: 10–16Google Scholar
  31. Kendal AP (1997) Cold-adapted live attenuated influenza vaccines developed in Russia: Can they contribute to meeting the need for influenza control in other countries? Eur J Epidemiol 13: 591–609PubMedCrossRefGoogle Scholar
  32. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ (1981) Development of cold-adapted recombinant live, attenuated influenza a vaccines in the USA and USSR. Antiviral Research 1: 339–365CrossRefGoogle Scholar
  33. Khan AS, Polezhaev F, Vasiljeva R et al. (1996) Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis 173: 453–456PubMedCrossRefGoogle Scholar
  34. Kilbourne ED (1969) Future influenza vaccines and the use of genetic recombinants. Bulletin of the World Health Organization 41: 643–5PubMedGoogle Scholar
  35. Klimov AI, Cox NJ, Yotov WV, et al. (1992) Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus. Virology 186: 795–797PubMedCrossRefGoogle Scholar
  36. Klimov AI, Egorov AY, Gushchina MI, et al. (1995) Genetic stability of cold-adapted reassortant vaccine strains before and after replication in children. J Gen Virol 76: 1521–1525PubMedCrossRefGoogle Scholar
  37. Klimov AI, Kiseleva IV, GI Alexandrova, Cox NJ (2001) International Congress Series: Options for the Control of Influenza IV, Osterhaus A, Cox N, Hampson A, eds Excerpta Medica, Amsterdam, p955–959Google Scholar
  38. Klimov AI, Rudenko LG, Egorov AY, Romanova JR, Polezhaev FI, Alexandrova GI, Cox NJ (1996) Genetic stability of Russian cold-adapted live attenuated reassortant influenza vaccines. In: Brown LE, Hampson AW, Webster RG (eds) Options for the Control of Influenza III, Elsevier Sciences B.V. pp 129–136Google Scholar
  39. Li S, Liu C, Klimov A, et al. (1999) Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. Journal of Infectious Diseases 179: 1132–8PubMedCrossRefGoogle Scholar
  40. Luytjes W, Krystal M, Enami M, Pavin JD and Palese P (1989) Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59: 1107–13PubMedCrossRefGoogle Scholar
  41. Maassab HF (1967) Adaptation and growth characteristics of influenza virus at 25°C. Nature 213: 612–614PubMedCrossRefGoogle Scholar
  42. Maassab HE 1968. Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 102: 728–732Google Scholar
  43. Maassab HF, Kendal AP, Abrams GD, Monto AS (1982) Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 146: 780–790PubMedCrossRefGoogle Scholar
  44. Meltzer MI, Cox NJ, Fukuda K (1999) The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 5: 659–671PubMedCrossRefGoogle Scholar
  45. Mendelman PM, Cordova J, Cho I (2001) safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted ( CAIV-T) in healthy children and healthy adults. Vaccine 19: 2221–2226Google Scholar
  46. Mills J, Chanock RM (1971). Temperature-sensitive mutants of influenza virus. I. Be- haviour in tissue culture and in experimental animals. J Infect Dis 123: 145–157Google Scholar
  47. Murphy BR, Coelingh K (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15: 295–323PubMedCrossRefGoogle Scholar
  48. Murphy BR, Hinshaw VS, Sly DL, et al (1982a) Virulence of avian influenza A viruses for squirrel monkeys Infect immune 37: 1119–1126Google Scholar
  49. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM (1982b) Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun 36: 1102–1108PubMedGoogle Scholar
  50. Murphy BR, Park EJ, Gottlieb P and Subbarao K (1997) An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 15: 1372–8PubMedCrossRefGoogle Scholar
  51. Muster T, Subbarao EK, Enami M, Murphy BR and Palese P (1991) An influenza A virus containing influenza B virus 5’ and 3’ noncoding regions on the neuraminidase gene is attenuated in mice. Proc Natl Acad Sci U S A 88: 5177–81PubMedCrossRefGoogle Scholar
  52. Neumann G, Kawaoka Y (2002) Synthesis of influenza virus: new impetus from an old enzyme, RNA polymerase I. Virus Research 82: 153–158Google Scholar
  53. Neumann G, Watanabe T, Ito H, et al. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proceedings of the National Academy of Sciences USA 96: 9345–50CrossRefGoogle Scholar
  54. Neumann G, Watanabe T and Kawaoka Y (2000) Plasmid-driven formation of influenza virus-like particles. Journal of Virology 74: 547–51PubMedCrossRefGoogle Scholar
  55. Neuzil KM, Mellen BG, Wright PF, Mitchel RF, Griffen MR (2000) Effect of influenza on hospitalization, outpatient visits, and courses of antibiotics in children. New Eng J Med 342: 225–31PubMedCrossRefGoogle Scholar
  56. Nichol KL, Wuorenma J, Von Sternberg T (1998) Benefits of influenza vaccination for low-intermediate- and high-risk senior citizens. Arch Intern Med 158: 176976Google Scholar
  57. Nicholson KG (1998) Human influenza In: Nicholson KG, Webster RG, Hay AJ (eds), Textbook of Influenza Blackwell Science Ltd, Oxford, pp 219–264Google Scholar
  58. Nicholson KG, Tyrrell DAJ, Oxford JS, et al. (1987) Infectivity and reactogenicity of reassortant cold-adapted influenza A/Korea/1/82 vaccines obtained from USA and USSR. Bull WHO 65: 285–301Google Scholar
  59. Palache AM (1997) Influenza vaccines: a reappraisal of their use. Drugs 54:841–856 Palese P, Garcia-Sastre A (2002) Influenza vaccines: present and future. Journal of Clinical Investigation 110: 9–13Google Scholar
  60. Parkin NT, Chiu P and Coelingh KL (1996) Temperature sensitive mutants of influenza A virus generated by reverse genetics and clustered charged to alanine muta-genesis. Virus Res 46: 31–44PubMedCrossRefGoogle Scholar
  61. Parkin NT, Chiu P and Coelingh K (1997) Genetically engineered live attenuated influenza A virus vaccine candidates. Journal of Virology 71: 2772–8PubMedGoogle Scholar
  62. Patriarca PA, Weber JA, Parker RA et al (1985) Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during influenza A (H3N2) epidemic. JAMA 253: 1136–1139PubMedCrossRefGoogle Scholar
  63. Peiris M, Yuen KY, Leung CW, et al. (1999) Human infection with influenza H9N2. Lancet 354: 916–7PubMedCrossRefGoogle Scholar
  64. Powers DC, Murphy BR, Fries LF, Adler WH, Clements ML (1992) Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc 40: 163–167PubMedGoogle Scholar
  65. Rudenko LG, Alexandrova GI (2001) Current strategies for the prevention of influenza by the Russian cold-adapted live influenza vaccine among different populations. In: international Congress Series 1219: Options for the Control of Influenza IV, Osterhaus A, Cox N, Hampson A, eds Excerpta Medica, Amsterdam, p945–950Google Scholar
  66. Rudenko LG, Arden NH, Grigorieva E, et al. (2001) Immunogenicity and efficacy of Russian live attenuated and US inactivated vaccines used alone and in combination in nursing home residents. Vaccine 19: 308–318CrossRefGoogle Scholar
  67. Rudenko LG, Slepushkin AN, Monto AS et al. (1993) Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 168: 881–887CrossRefGoogle Scholar
  68. Salvatore M, Basler CF, Parisien JP, et al. (2002) Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. Journal of Virology 76: 1206–1212PubMedCrossRefGoogle Scholar
  69. Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, Garcia-Sastre A and Palese P (2001) Plasmid-only rescue of influenza A virus vaccine candidates. Philos Trans R Soc Lond B Biol Sci 356: 1965–1973PubMedCrossRefGoogle Scholar
  70. Simonsen L, Clarke MJ, Schonberger LB, Arden NA, Cox NJ, Fukuda K (1998) Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis178: 53–60Google Scholar
  71. Snyder MH, Betts RF, De Borde D, et al. (1988) Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 62: 488–495PubMedGoogle Scholar
  72. Steinhoff MC, Halsey NA, Wilson MH et al. (1991) The A/Mallard/6750/78 avian-human but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children J Infect Dis 163: 1023–1028Google Scholar
  73. Subbarao K, Katz J (2000) Avian influenza viruses infecting humans. Cellular and Molecular Life Sciences 57: 1770–1784PubMedCrossRefGoogle Scholar
  74. Subbarao EK, Kawaoka Y and Murphy BR (1993a) Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation. J Virol 67: 7223–8PubMedGoogle Scholar
  75. Subbarao K, Klimov A, Katz J, et al. (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279: 393–6PubMedCrossRefGoogle Scholar
  76. Subbarao EK, London W, Murphy BR (1993b) A single amino acid in the PB2 gene of influenza A viruses is a determinant of host range. J Virol 67: 1761–1764PubMedGoogle Scholar
  77. Subbarao K, Chen H, Swayne D, et al. (2003) Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine. Virology in pressGoogle Scholar
  78. Subbarao EK, Park EJ, Lawson CM, Chen AY and Murphy BR (1995) Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. J Virol 69: 5969–77PubMedGoogle Scholar
  79. Subbarao EK, Perkins M, Treanor JJ, Murphy BR (1992) The attenuation phenotype conferred by the M gene of the influenza A/Ann Arbor/6/60 cold-adapted virus (H2N2) on the A/Korea/82 (H3N2) reassortant virus results from a gene constellation effect. Virus Res 25: 37–50PubMedCrossRefGoogle Scholar
  80. Takeda M, Pekosz A, Shuck K, Pinto LH and Lamb RA (2002) Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. Journal of Virology 76: 1391–1399PubMedCrossRefGoogle Scholar
  81. Talon J, Salvatore M, O’Neill RE, et al. (2000) Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proceedings of the National Academy of Sciences of the United States of America 97: 4309–4314PubMedCrossRefGoogle Scholar
  82. Tanaka T, Urabe M, Goto H and Tobita K (1984) Isolation and preliminary characterization of a highly cytolytic influenza B virus variant with an aberrant NS gene. Virology 135: 515–523PubMedCrossRefGoogle Scholar
  83. Tobita K, Tanaka T, Odagiri T, Tashiro M and Feng SY (1990) Nucleotide sequence and some biological properties of the NS gene of a newly isolated influenza B virus mutant which has a long carboxyl terminal deletion in the NS1 protein. Virology 174: 314–9PubMedCrossRefGoogle Scholar
  84. Tolpin MD, Massicot JG, Mullinex MG, et al. (1981). Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo. 112: 505–517Google Scholar
  85. Treanor JJ, Kotloff K, Betts RF, et al. (2000) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated influenza vaccine in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899–906CrossRefGoogle Scholar
  86. Watanabe T, Watanabe S, Ito H, Kida H and Kawaoka Y (2001) Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. Journal of Virology 75: 5656–62PubMedCrossRefGoogle Scholar
  87. Watanabe T, Watanabe S, Neumann G, Kida H and Kawaoka Y (2002) Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. Journal of Virology 76: 767–73PubMedCrossRefGoogle Scholar
  88. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of influenza A viruses Microbiol Rev 56: 152–179Google Scholar
  89. Wright PF, Webster RG (2001) Orthomyxoviruses. In: Knipe DM, Howley PM (eds) Fields’ Virology 4’h ed Lippincott-Raven, Philadelphia, pp 1533–1579Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • K. Subbarao
    • 1
  • J. M. Katz
    • 1
  1. 1.Influenza BranchCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations